(Q38014250)

27 August 2017

title

Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments (English)

1 reference

27 August 2017

0 references

1 reference

Michelle Lai

4

0 references

author name string

Charles A Inderjeeth

series ordinal

1

1 reference

27 August 2017

Kien Chan

series ordinal

2

1 reference

27 August 2017

Kevin Kwan

series ordinal

3

1 reference

27 August 2017

publication date

29 May 2012

1 reference

Journal of Bone and Mineral Metabolism

27 August 2017

published in

1 reference

27 August 2017

volume

30

1 reference

27 August 2017

issue

5

1 reference

27 August 2017

page(s)

493-503

1 reference

https://scigraph.springernature.com/pub.10.1007/s00774-012-0349-1

27 August 2017

exact match

0 references

cites work

Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Risk of new vertebral fracture in the year following a fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Risedronate prevents new vertebral fractures in postmenopausal women at high risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Efficacy of risedronate on clinical vertebral fractures within six months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

RETRACTED: Risedronate therapy for prevention of hip fracture after stroke in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Zoledronic acid and clinical fractures and mortality after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

First fractures among postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0349-1

Bone and joint diseases: prevention and control

21 January 2018

1 reference

12 December 2020

Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database

1 reference

12 December 2020

Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial

1 reference

12 December 2020

Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease [RETRACTED]

1 reference

12 December 2020

Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women

1 reference

12 December 2020

7: Treatment of osteoporosis: why, whom, when and how to treat. The single most important consideration is the individual's absolute risk of fracture.

1 reference

12 December 2020

Osteoporosis: underrated, underdiagnosed and undertreated.

1 reference

12 December 2020

Osteoporosis--diagnosis, treatment and management

1 reference

12 December 2020

Osteoporosis prevalence and levels of treatment in primary care: the Australian BoneCare Study

1 reference

12 December 2020

Treatment of postmenopausal osteoporosis

1 reference

12 December 2020

The crippling consequences of fractures and their impact on quality of life

1 reference

12 December 2020

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

1 reference

12 December 2020

Evidence‐based guidelines for fixing broken hips: an update

1 reference

12 December 2020

10.1007/S00774-012-0349-1

Identifiers

DOI

1 reference

27 August 2017

1 reference